Leqvio

Inclisiran, the active ingredient in Leqvio, is a PCSK9 inhibitor (siRNA) presented as a 284 mg injectable solution (prefilled syringe) for subcutaneous use. It treats heterozygous familial hypercholesterolemia, primary hypercholesterolemia and mixed dyslipidemia in adults. GNH USA supplies Leqvio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Leqvio is indicated for lipid‑lowering therapy in patients with elevated LDL‑cholesterol.

- Heterozygous familial hypercholesterolemia: reduces LDL‑cholesterol levels when added to statin therapy. - Primary hypercholesterolemia: lowers LDL‑cholesterol in patients at high cardiovascular risk. - Mixed dyslipidemia: improves lipid profile by decreasing LDL‑cholesterol alongside other lipid parameters.

Leqvio may be associated with adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site reactions: pain, erythema, or swelling at the injection site. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild headache. - Diarrhea: occasional loose stools.

Serious or Rare Side Effects: - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Hepatic enzyme elevation: increased ALT or AST levels. - Severe injection site necrosis: rare tissue damage at injection site. - Immune-mediated events: rare systemic hypersensitivity responses.

When prescribing Leqvio, clinicians should consider several safety and handling precautions.

- Cardiovascular monitoring: assess LDL‑cholesterol response and overall risk. - Concomitant statin therapy: continue statins as recommended to maximize LDL reduction. - Pregnancy and lactation: avoid use as safety has not been established. - Renal impairment: use with caution in patients with severe renal dysfunction. - Hepatic disease: monitor liver enzymes in patients with existing liver conditions. - Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Leqvio can interact with other medicines, primarily affecting lipid management and immune response.

Major Interactions (Avoid): - PCSK9 monoclonal antibodies: concurrent use may lead to redundant PCSK9 inhibition. - Live vaccines: potential altered immune response; avoid simultaneous administration.

Moderate Interactions (Monitor Closely): - Statins: monitor for additive LDL‑cholesterol lowering and rare myopathy. - Cytochrome P450 substrates: no direct effect, but monitor if hepatic function is compromised. - Anticoagulants: observe for any changes in coagulation parameters.